Suven Life Sciences working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

72.97×	72.97×	71.91×	32.67×	28.38×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.02×	0.01×	0.13×	0.05×	0.06×
0.02×	0.02×	0.03×	0.03×	0.05×
1.09×	1.09×	0.96×	0.79×	1.76×
1.06×	1.06×	0.93×	0.65×	1.65×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health

₹ CrorePeersVIMTALABS TAKEMcap ₹6,967 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Receivable Days (DSO)	28.38	32.67	71.91	72.97	72.97
Working Capital Turnover	0.06	0.05	0.13	0.01	0.02
Asset Turnover	0.05	0.03	0.03	0.02	0.02
Cash Conversion (CFO/Net Income)	1.76	0.79	0.96	1.09	1.09
CFO/EBITDA	1.65	0.65	0.93	1.06	1.06

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.